Home
|
About Us
|
Contact Us
|
The Process
|
Testimonials
|
Glossary
|
FAQS
|
Donations
The Process
Clinical Trials and Research
The Process
Services
Services offered
Traditional Cancer Treatment
Alternative Cancer Treatment
Labs: Coming Soon...
Testimonials
Amy L.
Isaac H.
Elliot F.
Patrick M.
Ben C.
Dr. Ernest V.
Frank M.
Missy M.
MZB Foundation
About The MZB Foundation
Donations
Case Histories
A Move from California...
Patient's Survival Serves as...
Unique Clinical Experience Gives...
Progress Reports
Patients and Caregivers
Physicians and Investigators
Tables
News
Latest News
9.16.20:
2020: Bruckner Oncology update
Analyses confirm 300% survival advantages and prognostic tests identify the 75% likely to benefit For the MZB Foundation for Cancer Research: "GFLIO" regimens are based on a series of confirmed laboratory discoveries. The methods have reversed resistance to six critical, standard drugs (Anticancer Research 16, 18). ✔️As reported - accepted at three international meetings in 2020, another three hundred new patients with pancreatic,...read more
Comments (0)
5.03.18:
2018: Womens Cancers
Anticancer Research}women's cancers 60-80-100% response rates Surg Clin NA} Neoadjuant twenty year survivors inoperable panc cancer ESMO} in press Colon new available drugs repurposed survival Research} updated Pancreatobiiliary updated safety eligibility survival }mscr in prep FDA Research} updates Stomach SBC immunotherapy personalized medicine target drugs survival Research} PARP BRCA 1/2 expanded to non BRCA and GI new co drugs Vaccines} FDA cell immunity pancreatic cancer GI oncology mscr...read more
Comments (0)
4.23.18:
Binah Magazine Article
Please click on the download below for a link to the Binah Magazine article featuring Dr. Bruckner!
Comments (0)
1.01.17:
2017: Pancreatic Cancer
AACR} pancreatic safety survival confirmed expanded high risk patients Vitamin C}personalized feasible assays broad application less invasive ASCO} eligibility six diseases see progress report < ASCO 16 Reverse resistance feasible 100,000 patients benefit a year or more Research} Personalized New hormones brain prostate panc 80% in vitro laboratory identified Novel safety of high dose ascorbic acid and induction chemotherapy for high...read more
Comments (0)
12.31.16:
2016: Safety
AntiCancer Research} bile duct cholangiocarcinoma target therapy new position confirm pancreatic asco 08 14 and gastric asco 06 expand role potency drugs 80% benefit ASCO} safety relief vitamin C trial reduces half of preexisting limiting toxicity six cancers Research} Update added Women's cancer confirm expand on AACR 14 Update added Hospice patients feasible majority live years > also > ASCO 17 >anticancer 18 Click on the...read more
Comments (0)
+ More Latest News
10.26.13:
Four new treatments produce 83-"100"% remissions of resistant ovarian cancer
October 24-27 COGI; Vienna, Austria: A treatment strategy (* cited below) has been modified for use against both resistant ovarian cancer and resistant endometrial cancer. A combination of interactive partner drugs can reverse a tumor's resistance to many drugs. For 30 patients, a new drug pair, Avastin and cyclophosphamide (ACy), known to...read more
Comments (0)
Our Process
...read more
Oncology Glossary
Latest News
09/16/20
2020: Bruckner Oncology update
05/03/18
2018: Womens Cancers
04/23/18
Binah Magazine Article
+ more news
Testimonials
Isaac H.
I’ve been a patient of Dr. Bruckner for three months ...read more